Clinical Trial: Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

This study is currently recruiting patients.

Sponsors and Collaborators: Cornell University Medical College
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining oxaliplatin with paclitaxel in treating patients who have locally recurrent or metastatic cervical cancer.

Condition Treatment or Intervention Phase
recurrent cervical cancer
stage IVA cervical cancer
stage IVB cervical cancer
cervical adenosquamous cell carcinoma
cervical squamous cell carcinoma
cervical adenocarcinoma
 Drug: oxaliplatin
 Drug: paclitaxel
 Procedure: chemotherapy
Phase II

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapy;   Cervical Cancer;   Soft Tissue Sarcoma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Oxaliplatin and Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer

Further Study Details: 


OUTLINE: Patients receive paclitaxel IV over 3 hours and oxaliplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 18-46 patients will be accrued for this study within 9-23 months.


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both



  • Histologically or cytologically confirmed cervical cancer of 1 of the following subtypes:
  • Squamous cell
  • Adenosquamous cell
  • Adenocarcinoma
  • Metastatic disease to organs or lymph nodes outside the pelvis OR
  • Locally recurrent disease in the pelvis after definitive therapy (surgery or radiotherapy) with at least 50% increase in size by sequential imaging studies
  • Measurable disease
  • At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • No known brain metastases


  • 18 and over

Performance status

  • ECOG 0-2 OR
  • Karnofsky 60-100%

Life expectancy

  • More than 2 months


  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin normal
  • AST/ALT no greater than 2.5 times upper limit of normal


  • Creatinine normal


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to oxaliplatin, cisplatin, carboplatin, paclitaxel, or docetaxel
  • No concurrent uncontrolled illness
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study compliance


  • Not specified


Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • See Chemotherapy
  • More than 4 weeks since prior radiotherapy and recovered


  • See Disease Characteristics
  • Recovered from prior surgery


Location and Contact Information

      Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington,  Connecticut,  06030-1614,  United States; Recruiting
Carolyn D. Runowicz, MD  860-679-2809 

New York
      Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx,  New York,  10461,  United States; Recruiting
Gary L. Goldberg, MD  718-430-3581 

      Herbert Irving Comprehensive Cancer Center at Columbia University, New York,  New York,  10032,  United States; Recruiting
Dawn Hershman, MD  212-305-1945 

      Mount Sinai School of Medicine, New York,  New York,  10029,  United States; Recruiting
Jamal Rahaman, MD  212-241-6500 

      New York Weill Cornell Cancer Center at Cornell University, New York,  New York,  10021,  United States; Recruiting
Dennis Yi-Shin Kuo, MD  212-746-4750 

      NYU Cancer Institute at New York University Medical Center, New York,  New York,  10016,  United States; Recruiting
Stephanie V. Blank, MD  212-263-2668 

Australia, New South Wales
      Sydney Cancer Centre at Royal Prince Alfred Hospital, Sydney,  New South Wales,  2050,  Australia; Recruiting
Anne Hamilton, MD, FRACP  61-2-9515-5894 

Study chairs or principal investigators

Dennis Yi-Shin Kuo, MD,  Study Chair,  Cornell University Medical College   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000277249; NYWCCC-0902-492; NCI-5840; NCT00057863
Record last reviewed:  March 2003
Last Updated:  April 4, 2005
Record first received:  April 7, 2003 Identifier:  NCT00057863
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005